Devices and methods for enrichment and alteration of circulating tumor cells and other particles

• US 20070026413A1
• Filed: 12/29/2005
• Published: 02/01/2007
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Mehmet Toner
• Inventors: Toner, Mehmet, Fuchs, Martin
• Application Number:
  US11/322,790
• Publication Number:
  US 20070026413A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism

Abstract

The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Claims

1. A device for processing a cellular sample, said device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells, wherein said device is capable of processing at least 20 mL of fluid per hour.

2. The device of claim 1, wherein said structure comprises an array of obstacles that form a network of gaps.

3. The device of claim 2, wherein said gaps are between 20 and 100 microns in size.

4. The device of claim 2, wherein said array of obstacles comprises a staggered two-dimensional array of obstacles.

5. The device of claim 2, wherein said array of obstacles comprises a plurality of rows, each successive row being offset by less than half of the period of the previous row.

6. The device of claim 2, further comprising one or more additional arrays of obstacles in series or in parallel with said first array of obstacles.

7. The device of claim 1, wherein said first cells have a larger average hydrodynamic size than said second cells.

8. The device of claim 1, wherein said device is capable of processing at least 50 mL of fluid per hour.

9. The device of claim 1, wherein said cellular sample comprises blood or a fraction thereof.

10. The device of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than 12 microns in said first direction.

11. The device of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than 14 microns in said first direction.

12. The device of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than 16 microns in said first direction.

13. The device of claim 1, said device comprising a continuous flow device comprising a first inlet, a first outlet, and a second outlet, wherein said cellular sample is applied to said first inlet, said first output sample flows out of said first outlet, and said second output sample flows out of said second outlet.

14. The device of claim 1, wherein said device is capable of producing a first output sample enriched in said first cells, wherein the volume of said first output sample is smaller than the volume of said cellular sample.

15. The device of claim 1, wherein said first output sample comprises at least 80% of said first cells in said cellular sample.

16. The device of claim 1, wherein said second output sample comprises less than 20% of said first cells in said cellular sample.

17. The device of claim 13, wherein said device comprises a second inlet, and wherein a second fluid is applied to said second inlet

18. The device of claim 1, wherein said first cells comprise epithelial cells, cancer cells, bone marrow cells, fetal cells, progenitor cells, stem cells, foam cells, mesenchymal cells, immune system cells, endothelial cells, endometrial cells, connective tissue cells, trophoblasts, bacteria, fungi, or pathogens.

19. The device of claim 1, said device further comprising a detector module fluidically coupled to said channel.

20. The device of claim 19, wherein said detector module comprises a microscope, a cell counter, a magnet, a biocavity laser, a mass spectrometer, a PCR device, an RT-PCR device, a matrix, a microarray, or a hyperspectral imaging system.

21. The device of claim 20, wherein said detector module detects a label that selectively binds said first cells.

22. The device of claim 1, wherein said device is adapted for implantation in a subject.

23. The device of claim 22, wherein said device is adapted for placement in or near the circulatory system of a subject.

38. The device of claim 1, wherein said channel comprises an array of obstacles forming a network of gaps, and wherein fluid flows through said gaps such that said fluid is divided unequally into a major flux and a minor flux.

24. A system that is capable of being fluidically coupled to the circulatory system of a subject, said system comprising a device for processing a cellular sample, said device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells.

25. The system of claim 24, wherein said system is fluidically coupled to said circulatory system through tubing or an arteriovenous shunt.

26. The system of claim 24, wherein said system is capable of removing one or more analytes from said circulatory system.

27. The system of claim 24, wherein said system is adapted for continuous blood flow through said device.

28. The system of claim 24, wherein said device is disposable.

29. A method for depleting an analyte from a cellular sample, said method comprising introducing said cellular sample into a device for processing a cellular sample, said device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells, wherein said first output sample or said second output sample is depleted in said analyte relative to said cellular sample.

30. The method of claim 29, wherein said cellular sample comprises blood, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, secretions of the respiratory, intestinal or genitourinary tract, amniotic fluid, or a water sample.

31. The method of claim 29, wherein said cellular sample is taken from a subject afflicted with a hematological condition, an inflammatory condition, an ischemic condition, a neoplastic condition, infection, trauma, endometriosis, or kidney failure.

32. The method of claim 29, wherein said neoplastic condition is selected from the group consisting of acute lymphoblastic leukemia, acute or chronic lymphocyctic or granulocytic tumor, acute myeloid leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoma, adrenal cancer, basal cell carcinoma, bone cancer, brain cancer, breast cancer, bronchi cancer, cervical dysplasia, chronic myelogenous leukemia, colon cancer, epidermoid carcinoma, Ewing'"'"'s sarcoma, gallbladder cancer, gallstone tumor, giant cell tumor, glioblastoma multiforma, hairy-cell tumor, head cancer, hyperplasia, hyperplastic corneal nerve tumor, in situ carcinoma, intestinal ganglioneuroma, islet cell tumor, Kaposi'"'"'s sarcoma, kidney cancer, larynx cancer, leiomyomater tumor, liver cancer, lung cancer, lymphomas, malignant carcinoid, malignant hypercalcemia, malignant melanomas, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuromas, mycosis fungoide, myelodysplastic syndrome, myeloma, neck cancer, neural tissue cancer, neuroblastoma, osteogenic sarcoma, osteosarcoma, ovarian tumor, pancreas cancer, parathyroid cancer, pheochromocytoma, polycythemia vera, primary brain tumor, prostate cancer, rectum cancer, renal cell tumor, retinoblastoma, rhabdomyosarcoma, seminoma, skin cancer, small-cell lung tumor, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, thyroid cancer, topical skin lesion, veticulum cell sarcoma, and Wilm'"'"'s tumor.

33. A method for diagnosing a condition in a subject, said method comprising the steps of:

a) introducing a cellular sample from said subject into a device for processing a cellular sample, said device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells, wherein said device is capable of processing at least 20 mL of fluid per hour;

b) analyzing said first output sample; and

c) diagnosing the presence or absence of said condition based on the results of step b).

34. The method of claim 33, wherein step b) comprises analyzing the cells of said first output sample for one or more characteristics selected from the group consisting of adhesion, migration, binding, morphology, division, level of gene expression, and presence of a somatic mutation.

35. The method of claim 33, wherein step b) comprises detecting the presence or absence of one or more markers selected from Table 1, detecting the presence or absence of a mutation in a nucleic acid that encodes one or more markers selected from Table 1, detecting the presence or absence of a deletion in a nucleic acid that encodes one or more markers selected from Table 1, detecting the level of expression of one or more markers selected from Table 1, or detecting the level of microRNA in said first output sample.

36. The method of claim 33, wherein said condition is a hematological condition, an inflammatory condition, an ischemic condition, a neoplastic condition, infection, trauma, endometriosis, or kidney failure.

37. The method of claim 33, wherein step b) comprises determining the number of said first cells in said first output sample.